CGTLive’s Weekly Rewind – August 25, 2023


Review top news and interview highlights from the week ending August 25, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR-M/Pembrolizumab Trial Doses First Patient With HER2-Overexpressing Solid Tumors

Initial data from the combination substudy are expected in the second half of 2023.

2. Robert J. Hariri, MD, PhD, on the Importance of Placental-Derived Stem Cells in Cell Therapy

The founder, chairman, and CEO of Celularity discussed the advantages of cells derived from umbilical cord blood versus other sources of cells for cell therapies.

3. Gene Therapy Improves Grade 2/3 Xerostomia Symptoms

Participants treated both unilaterally or bilaterally reported clinically meaningful improvements on GRCQ and XQ scale scores.

4. Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy

The interventional cardiologist and professor, Duke University School of Medicine, discussed how XC001 could improve outcomes for patients with refractory angina.

5. Gaucher Disease Type 1 Gene Therapy Trial Proceeds to Dose Second Cohort

The company announced that it had completed dosing in the first cohort of the GALILEO-1 trial of FLT201.

Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
Fiona Freeman, PhD, on Investigating miRNA-29b in Osteosarcoma Models
Paul Harmatz, MD, on Challenges With Assessing Neurocognitive Outcomes
Brian Van Tine, MD, PhD, on Progress and Challenges With Cell Therapy for Sarcoma
J. Andrew Livingston, MD, on Potential Advantages of TCR NK Therapy for Synovial Sarcoma and MRCL
Farah Sheikh, PhD, on Continuing Gene Therapy Research Into Arrhythmias, Cardiac Dysfunction
© 2023 MJH Life Sciences

All rights reserved.